BRAF and lung carcinoma: Tumors with mutations in BRAF (7% of lung cancers) may be treated with vemurafenib or dabrafenib, and tumors with rearrangements involving ALK and/or ROS1 (1–2% of lung cancers) may be treated with crizotinib, ceritinib or alectinib [17].